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The factors influencing cancer susceptibility and why it varies across species
are major open questions in the field of cancer biology. One underexplored
source of variation in cancer susceptibility may arise from trade-offs between
reproductive competitiveness (e.g. sexually selected traits, earlier repro-
duction and higher fertility) and cancer defence. We build a model that
contrasts the probabilistic onset of cancer with other, extrinsic causes of mor-
tality and use it to predict that intense reproductive competition will lower
cancer defences and increase cancer incidence. We explore the trade-off
between cancer defences and intraspecific competition across different
extrinsic mortality conditions and different levels of trade-off intensity,
and find the largest effect of competition on cancer in species where low
extrinsic mortality combines with strong trade-offs. In such species, selection
to delay cancer and selection to outcompete conspecifics are both strong, and
the latter conflicts with the former. We discuss evidence for the assumed
trade-off between reproductive competitiveness and cancer susceptibility.
Sexually selected traits such as ornaments or large body size require high
levels of cell proliferation and appear to be associated with greater cancer
susceptibility. Similar associations exist for female traits such as continuous
egg-laying in domestic hens and earlier reproductive maturity. Trade-
offs between reproduction and cancer defences may be instantiated by a var-
iety of mechanisms, including higher levels of growth factors and hormones,
less efficient cell-cycle control and less DNA repair, or simply a larger
number of cell divisions (relevant when reproductive success requires
large body size or rapid reproductive cycles). These mechanisms can affect
intra- and interspecific variation in cancer susceptibility arising from rapid
cell proliferation during reproductive maturation, intrasexual competition
and reproduction.
1. Introduction
Cancer incidence across species varies widely. These differences in cancer sus-
ceptibility are due to both environmental exposures [1], and evolutionary
pressures shaping organism-level cancer susceptibility and cancer defences
[2–4]. Beneficial traits such as defence against disease are often costly, and
such trade-offs can maintain genes that contribute to disease susceptibility [5].
For example, trade-offs between reproduction and immune defence have been
observed in a number of species [6,7]. Similar trade-offs have been proposed to
underlie observed associations between reproductive competitiveness and
cancer [8], though as of yet there has been no formal model describing these
trade-offs and the factors affecting them.
& 2015 The Author(s) Published by the Royal Society. All rights reserved.
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Accumulating genetic and molecular evidence suggests
that trade-offs between benefits early in life and disease suscep-
tibility later in life may be widespread across disease (as
reviewed in Carter & Nguyen [9] and Leroi et al. [10]). This
phenomenon may also significantly shape the susceptibility
to cancer [9]. Cancer suppressor genes such as P53 [11,12]
and BRCA [13] play important roles in fertility and may be
maintained owing to trade-offs between fertility enhancement
and cancer risk.
Trade-offs between reproductive competitiveness and
cancer risk can be expected for two main reasons: (i) selection
for mechanisms that enable rapid cell proliferation could
simultaneously enhance extreme trait expression as well as
tumour formation and (ii) selection for increased allocation of
energy to reproductive traits rather than to somaticmaintenance
could elevate cancer risk by increasing somatic mutation rates.
The first type of trade-off may involve mutations or epigenetic
silencing of cancer suppression genes. The second type of
trade-off could be due to altered allocation of a finite energy
pool towards reproduction at the expense of somatic mainten-
ance, such as DNA repair or immune defences. Consequently,
mutations that increase cancer risk arise more easily if energy
must be diverted away from DNA repair to support develop-
ment or expression of reproductive traits. These two pathways
are distinct, but can potentially interact to produce trade-offs
between reproductive competitiveness and cancer suscepti-
bility. Even if somatic mutation rate per cell division did not
change, reproductive success might require a larger number of
cell divisions (e.g. when sexual selection favours large-bodied
males), and this again increases the total risk.
In this paper, we explore the effect of reproductive trade-offs
on the evolution of cancer defences, modelling reproductive
competitiveness as the extent towhich themost competitive indi-
vidualsdominate reproduction.Reproductive competitiveness is
an important force in the evolution of extreme morphologies
and life histories, and is often impacted by sexual selection [14].
Traits such as large bodysize, extrememorphology (i.e.weapons
or ornaments), larger and more frequent litter size, and
aggressiveness can all have positive effects on fitness through
preferential mating or differential fitness owing to higher repro-
ductive output, but they can also be costly in terms of increasing
mortality or morbidity. Large body size and extreme mor-
phologies often require greater levels of cell proliferation via an
increase in growth signalling mechanisms (including hormones
andgrowth factors). Additionally, factors that accelerate organis-
mal reproduction (e.g. growing fast, earlymaturation) or increase
the frequency of reproduction might enhance cancer risk
through the allocation of energy towards reproduction rather
than through somatic maintenance, potentially increasing the
likelihood of mutations in cancer suppressor genes.
Our model does not explicitly distinguish between these
two types of trade-offs (cell-proliferation-related vulnerabilities
and energy allocation trade-offs). For simplicity and generality,
we base our model on the intensity of the trade-off be-
tween reproductive competitiveness and cancer defences. In
addition to varying the intensity of the trade-offs, we also
consider varying levels of extrinsic mortality. This allows us
to explore the evolutionary viability of cancer defences in
species under different reproductive, social and ecological con-
ditions. Mortality (and the consequent expected lifespan) is
important, because cancer defences can delay the onset of
cancer, but delays bring about little selective benefit at an
age where the organism is likely to have died of other causes.
We use this model to make predictions about the patterns of
cancer incidence across species and reviewavariety ofmechan-
isms that might underlie trade-offs between reproductive
competitiveness and cancer defence.
2. Model
(a) Stronger intraspecific competition is predicted
to lead to higher cancer incidence
Can reproductive competition within a population lead to indi-
viduals adaptively ‘neglecting’, or never evolving, some of the
possible defences against cancer? Here, we derive an optimality
model to address this question, as well as whether populations
with particularly strong intraspecific competitive effort should
be expected to have an elevated risk of mortality owing to
cancer (as opposed to someother cause). In thismodel, the popu-
lation can refer to all individuals, regardless of their sex, but it is
also possible to make statements about a subset of the biological
population to the extent that competition occurs among ‘peers’.
For example, the populationmay be split intomales and females,
which means that other males form the relevant peer group of
males, whereas females compete with other females. Conse-
quently, we also consider whether male defences against
cancer are expected to differ from those of females.
(b) Model assumptions and derivations
(i) Cancer defence
First, we assume that variation in the strength of defences
against cancer is present in the population. The model does
not specify how the defence acts to delay cancer onset. Instead,
we use an operational definition. Assuming that cancer takes
n steps to form, with each occurring at a rate ki per cell, where
i ¼ 1, 2, . . . ,n, ifn stepshaveoccurred in aparticular cell lineage,
then the whole organism has cancer. The organism possesses
defence levels di against each step i, where 0 ! di ! 1. Each di
denotes the reduction in the rate at which the corresponding
step occurs: if, for example, di ¼ 0.5, the ith step takes, on aver-
age, twice as long to happen than it would in the absence of
any defence; if di ¼ 0.75, it takes four times as long (only 25%
of the rate then remains, and 1/0.25 ¼ 4). One possible way to
achieve di ¼ 0.5 is to haveDNA repair remove half of the critical
mutations, but less direct ways include efficient immuno-
competence that clears half of the infections before they
can heighten the organism’s cancer risk. Alternatively, the
organism may simply eliminate half of the precancerous cells.
For simplicity, our examples are built assuming that all limit-
ing steps occur at the same rate ki ¼ k for all i, and that cancer
defence likewise is the same across steps, di ¼ d for all i. Without
this assumption, the analysis would proceed as below but with
specific multiplications for each i separately. The general model
intends to make no statements about the relative efficiency of
particular defence types against specific rate-limiting steps.
(ii) Reproductive competition within the peer group
Next, we specify how intraspecific competition impacts
an individual’s reproductive success. As described in §1,
trade-offs between defence and investment in immediate
reproductive success may occur for multiple reasons. For
example, the latter may require fast growth, but this comes
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function of two parameters a (the intensity of intraspecific
competition) and b (the strength of trade-offs): the rate of
fitness accumulation per time unit spent alive and cancer
free is assumed proportional to ca ¼ (1 – db)a.
This is specified as ‘proportional to’ rather than as ‘equal to’
to take into account the fact that fitness is relative to conspeci-
fics. Thus, if surrounded by many other competitive
individuals, fitness of the focal individual may remain low,
but for the subsequent analysis contrasting alternative life his-
tories of a focal individual the effect of others stays constant
and does not have to be included [15]. Here, c ¼ 1 – db
describes the individual’s competitiveness assuming it does
not yet have cancer. Cancerous individuals are assumed to
be non-competitive and thus gain zero reproductive success
while alive with cancer.
Competitiveness, as defined above, is a declining function
of cancer defences, which reflects the assumption that defences
are costly. The parameter a describes the intensity of intraspe-
cific competition (in many cases, limited to competition within
a sex, i.e. intrasexual competition) such that resources obtained
scale with competitiveness according to a power function ca
(see parameter u in an analogous treatment in [15]). Thus, if
a ¼ 1, an individual whose competitiveness c exceeds that of
its peer group by a certain percentage (say, 10%) will have an
equivalently better (in this example 10%) access to resources.
If a, 1, the benefits of increased competitiveness are lower:
a 10% increase in c would, then, lead to lower than 10%
improvement in reproductive gains. Conversely, a. 1 will
make the resource–competitiveness relationship steeper, so
that if a" 1, competition is of a ‘winner-takes-all’ nature: a
higher competitiveness, c, compared with the rest of the peer
group will then lead to the focal individual reaping almost
all the reproductive benefits.
The parameter b changes the shape of trade-offs: if b is
small, then competitiveness declines in response to investing in
other life-history components (here, cancer defence) even if the
defence is not intensive; ifb is large, then individuals can retain
their competitiveness intact up to high (d # 1) defence levels.
Individuals are assumed to gain reproductive payoffs (of
magnitude ca) at a constant rate as long as they are cancer-free
and have also avoided other sources of mortality.
(iii) Cancer-free lifespan
There are two ways in which an individual can end its repro-
ductive career. The first is death owing to a source of
mortality other than cancer, which we assume occurs at a con-
stant rate, m. A(t) is the probability that this type of death has
happened by time t. The second way an individual can die is
by cancer, that is, when one of the N cell lineages has passed
through all the rate-limiting steps, denoted by B(t), the prob-
ability that this has happened by time t. The overall
probability that the individual is alive is
P(t) ¼ (1% A(t))(1% B(t)), ð2:1Þ
where
A(t) ¼ e%mt ð2:2Þ
and
B(t) ¼ 1% (1% (1% e%(1%d)kt)n)N ð2:3Þ
B(t) is formed in the following way: 12 e– (12 d)kt is the prob-
ability that a single rate-limiting step has already happened
by time t. When we assume that n steps are required before
oncogenesis can end an individual’s reproductively active
life, (12 e2(12d )kt)n is the probability that all of them have hap-
pened in the same focal cell lineage. The complementary
probability 12 (12 e2(12d )kt)n consequently gives the prob-
ability that the focal lineage is healthy at time t. If there are N
such lineages in an organism, (12 (12 e2(12d )kt)n)N (which
raises the above to the power N) is the probability that all cell
lineages are healthy at time t. The complement of this quantity
is the probability B(t) of cancer having already emerged in at
least one cell lineage as indicated above.
In the absence of any defences against cancer, the prob-
ability that the individual has cancer by time t rises from
zero to unity as time passes (figure 1). The effect of defence
is to delay this increase in a very specific manner: for each
value of d, the cumulative probability curves of cancer
having ended the individual’s cancer-free lifespan are shifted
to the right such that any horizontal time line drawn from t ¼
0 to the probability curve has exactly the proportion d spent
in the state of ‘cancer-free life prolonged due to defences’.
Thus, if, for example, d ¼ 0.75, one-quarter of the age that
the organism managed to spend cancer-free was caused by
‘luck’, whereas three-quarters can be attributed to defences
delaying the eventual inevitability of cancer.
To sum up the effect of d on realized lifespan, however, it is
not sufficient to stop at the information contained in figure 1,
because other sources of mortality can make it unlikely that
the organism is alive to reap the probabilistic benefits of the
longest delays at the upper end of figure 1. In this context, it
is insightful to use equation (2.3) to derive the time, denoted
t(P, d), that it takes cancer incidence to reach any pre-specified
value P, for a given level of defences d
t(P, d) ¼ %









1% A(t(P, d))dP ð2:5Þ
Numerical integration of L(d ) leads to a crucial insight. If
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Figure 1. Higher cancer defence increases lifespan. The probability that
cancer has arisen by age t for three different defences d ¼ 0, d ¼ 0.5
and d ¼ 0.75. Note that for any probability level, d indicates the proportion
of the arrow that extends beyond the d ¼ 0 curve. Thus, e.g. with d ¼ 0.75,
three quarters of the delay from birth to cancer is due to the defence effort,
one quarter owing to the time that mutations take to occur even if there is
no cancer defence effort. Graphs are derived using parameters k ¼ 0.01,
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in defence, d, does not prolong lifespan. Even in the absence
of defences, cancer remains an insignificant cause of death as
it does not ‘have the time’ to develop before the organism has
already been killed by predators or any other factors categor-
ized as extrinsic mortality (m). Only when these other sources
of mortality are low (left side of figure 2), does investing in
defence, d, have a substantial impact on lifespan. This high-
lights that in our aim to derive how optimal cancer
defences depend on intraspecific competition (parameters a
and b), we also must consider scenarios with a variety of
extrinsic mortalities (m).
To derive how optimal cancer defences depend on intraspe-
cific competition, while considering scenarios with a variety of
extrinsic mortalities (m), we compute lifetime fitness, i.e. the
quantity (1 – db)aL(d), for different extrinsic mortalities and
intraspecific competition (a) and trade-off (b) values and find
themaximum.Theresults (figure3) show that in all themortality
scenarios (m ¼ 0.01, 0.1 and 1) and whether we assumeweak or
strong trade-offs (b) between cancer defences and reproductive
success, the optimal defence always declines with increasing
intraspecific competition (a), unless defence is already low to
begin with (top right figure). The results remain similar across
all values of n and N that we tested, though for simplicity only
one set of parameters is shown. Lastly, we present alternative
extrinsic mortality (m) scenarios and illustrate how often life is
actually ended by cancer, as opposed to all other causes. More
intense intraspecific competition (a) increases mortality risk by
cancer unless trade-offs (b) are low (figure 4).
3. Predictions from the model
(a) High intraspecific competition lowers cancer
defences
Our model predicts that individuals may evolve traits that
increase reproductive success even if this increases their
cancer risk, but the extent to which this applies depends on
the intensity of intraspecific (often intrasexual) competition as a
determinant of reproductive success, and also other parameter
values. In an environment with low extrinsic mortality (m ¼
0.01), we expect more cancer in species where intraspecific
competition (a) is very strong (at the extreme, of a winner-
takes-all nature; figure 3 top left). Species in high extrinsic
mortality environments (m ¼ 1), on the other hand, are expected
to die from other causes than cancer, regardless of the intensity
of intraspecific competition (a) (figure 4c). If extrinsic mortality
is lower, then cancer incidence can depend strongly on the role
that intraspecific competition (a) plays in shaping life histories
(figure 4a,b). Intraspecific competition can vary between males
and females, and thus we will discuss our predictions and
review of the literature separately for each sex.
(i) Sexually selected traits may increase cancer risk
in highly competitive males
Males often invest more energy in obtaining a mate than
females and this can lead to high competition among individ-
uals to reproduce. For example, males with high reproductive
competitiveness participate in male–male competition
and dominant males gain more opportunities to mate. This
competition can favour the evolution of secondary sexual
characteristics (e.g. extreme traits) [14,16], and it is well
known that a shorter lifespan may be an ‘acceptable’ cost of
such traits in the sense that net selection favours their exagger-
ation, whereas male lifespan is shortened. According to our
model, we predict sexually dimorphic species, such as individ-
uals with extreme ornaments andweapons or larger body size,
to be subject to increased cancer risk (figure 5); similarly, we
expect more cancer in species with strong sperm competition
(particularly in the relevant tissues such as the testes). These
trade-offs may be a result of vulnerabilities arising from
increased cell proliferation (e.g. growth promoting signals to
produce large body size or weapons; more of the continually
dividing cells in larger testes) or as a result of allocation of
energy towards reproductive competition at the expense of
somatic maintenance (e.g. DNA repair, immune defences).
However, it is clearly difficult to obtain cancer incidence for
species in the wild, especially when male–male competition
is intense: poor performance of an individual after the onset
of cancer can lead to a death (e.g. taken by a predator) that is
not easy to trace back to cancer.
There is some evidence to suggest that selection for large
body size in males can lead to higher cancer susceptibility.
For example, Xiphophorus maculatus, a freshwater fish called
the Southern platyfish, carries a dominant oncogene (Xipho-
phorus melanoma receptor kinase, Xmrk) that is normally
suppressed but can result in the formation of male-biased
malignant melanomas in hybrids [17–20]. Body size can
strongly predict reproductive success in this species, and
the Xmrk genotype is positively correlated with a larger
body size in both males and females. Females prefer to
mate with males carrying a larger black spot [17,18], and
males with melanoma and Xmrk were significantly longer
than both males with Xmrk and no melanoma and males
without Xmrk [17]. Xmrk is derived from a gene duplication
event of an epidermal growth factor receptor that controls
cell proliferation [21], and it may be involved in binding to
growth factor ligands that increase both body size and
melanoma formation in several Xiphophorus species [22].


























Figure 2. The effects of cancer defences on lifespan are strongest when extrin-
sic mortality is low. Model predictions for the expected duration of cancer-free
life, which can be ended by either cancer or through other sources of mortality,
as a function of extrinsic mortality m, plotted for different values for defence
effort d as indicated on the graph (lowest curve: d ¼ 0, then d ¼ 0.1, fol-
lowed by d ¼ 0.5 and d ¼ 0.9). The dotted line gives the expected
lifespan assuming no cancer ever occurs (d ¼ 1). The impact of defence on
lifespan varies from strong when extrinsic mortality is low, to negligible
when lifespans are short owing to causes other than cancer. Parameters as
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Another intriguing example of a trait that can enhance
reproductive competitiveness of males, but also may increase
cancer risk is the production of sexually selected weapons,
such as antlers. In most deer species, only males grow antlers,
and growth is initiated at puberty [23,24]. New antler growth
and casting is seasonal, and thought to be controlled by levels
of circulating testosterone [25,26]. It has been hypothesized
that there is also a period of androgen-independent growth
during antler formation [23], where circulating levels of
insulin-like growth factor-1 (IGF-1) were significantly increa-
sed in male deer growing their antlers [27]. Male–male
competition can lead to strong selection for growth to produce
such elaborate traits, but this comeswith a risk: disregulation in
the system can lead to uncontrolled cellular growth. Species
with antlers are accordingly susceptible to antleromas, which
are massive growths found on the antlers of free ranging
deer [28–35]. Antleromas can be artificially produced when
androgen production is disrupted (e.g. castration) and circulat-
ing testosterone does not cycle [32], suggesting that interactions
between hormone levels and growth factors underlie the
mechanisms creating susceptibility to antleromas.
(ii) Factors that enhance female fertility may lead
to elevated cancer risk
In many species, females invest typically more heavily in other
components of reproductive effort rather than mating effort.
Determinants of reproductive success for females often include
components such as fertility timing and frequency, as well as
size of the litter and investment in individual offspring. Our
model is not sex-specific per se: although intraspecific compe-
tition (a) is probably lower for most females compared with
males (reproduction is not of a ‘winner-takes-all’ nature), it
still predicts that investment in traits that elevate reproductive
competitiveness can elevate susceptibility to cancer, especially
if very high reproductive output requires rapid cell prolifer-
ation (figure 4). Given that early reproductive maturity and
rapid offspring production both require rapid cell proliferation,
and may also involve the allocation of energy towards repro-
duction at the expense of DNA repair, we consider it possible
that selection for improved reproductive success can lead to
higher cancer risk in females, too.
Once again, detecting cases in the wild remains challen-
ging: natural selection can yield life histories where most
deaths occur before the expected onset of cancer (figure 4).
Artificial breeding, however, offers instructive examples for
revealing underlying trade-offs: intense selection for reproduc-
tive traits can heighten cancer risk considerably (figure 5). The
domesticated Jungle fowl hen (Gallus gallus domesticus) has
been artificially selected for daily ovulation and continuous
egg-laying. This hen is the only known non-human animal
with a high incidence of spontaneous ovarian cancer [36].
Ovarian cancer is observed in hens as young as 2 years of
age, and 30–35% develop the highly malignant disease by
3.5 years of age [36,37].
4. Discussion
(a) Life-history trade-offs between cancer defences
and reproduction
One way reproductive competition may be lowering cancer




























































































intraspecific competition (a) intraspecific competition (a) intraspecific competition (a)
Figure 3. Intraspecific competitiveness has the strongest effect on cancer risk in environments with low extrinsic mortality and strong trade-offs. When extrinsic
mortality is low (m ¼ 0.01) and trade-offs between cancer defence and reproductive competition is high (b ¼ 1), as intraspecific competition increases (a), cancer
defences remain high until a critical threshold is reached (when intraspecific competition is greater than 1) and then dramatically declines (upper left). Cancer
defence declines in all cases with a, but is sometimes low to begin with (upper right corner where extrinsic mortality is high). Parameters as in figure 1
and figure 2, and additionally b ¼ 1, 2 or 5 (top, middle and bottom row, respectively), and m ¼ 0.01, 0.1 or 1 (left, middle and right column, respectively).
Colours indicate the fitness consequences of each possible level of defence effort (0 ! d ! 1 as indicated on the y axis) for value of intraspecific competition (a)





 on June 8, 2015http://rstb.royalsocietypublishing.org/Downloaded from 
have limited energy to divide between soma maintenance and
reproduction, with allocations dependent on life history (see
‘disposable soma theory’ [39]). Short-lived organisms allocate
more resources towards reproduction in order to reproduce suc-
cessfully within their lifespan, whereas investment in somatic
maintenance (among them cancer defences) has allowed
species to extend their lifespans [40,41]. When all else is equal,
short-lived rodents are more prone to cancer [42,43] than are
long-lived species, such as elephants and whales [3]. Indicative
of lower defences, cells of shorter-lived organisms overcome
intrinsic growth limitations more easily (i.e. transformation in
cell culture) [44], allocate less time to DNA repair (short-lived
species have more unresolved DNA damage in the form of
micronuclei) [45] and proliferate rapidly in vitro [46]. Our results
suggest that large-bodied animals must invest more in somatic
maintenance, including tumour suppression, to build and
maintain a large body for a sufficiently long time for reproduc-
tion to occur [3,47]. It has also been demonstrated that DNA
break recognition is better in mammals with long lifespans
[48]. Increasing lifespan may thus select for new tumour sup-
pressor mechanisms or a shift in energy allocation towards
more prolonged somatic tissue maintenance [49].
Some of the genetic and molecular mechanisms that
mediate trade-offs between cancer defences and reproduction
are becoming better understood. For example, the cancer
suppressor genes P53 [11,12] and BRCA [13] are likely candi-
dates given that mutations in these genes appear to be
associated with enhanced fertility in some cases. Current evi-
dence suggests that the P53 family of tumour suppressors
(which includes also p63 and p73) may be involved in fertility
and reproduction as well as cell cycle regulation [50]. Mouse
models have demonstrated that p63 may have effects on the
quality and survival of the oocyte pool [51], p73 plays a
role in early blastocyst division [52], and p53 may help regu-
late the implantation of the fertilized egg as well as litter size
in knockout mice [53].
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Figure 4. Stronger intraspecific competition increases the probability of cancer. The incidence of cancer, measured as the probability of cancer rather than
extrinsic mortality ending an individual’s reproductively active life, increases as a function of reproductive competition (a) under three different extrinsic mortalities
(a) m ¼ 0.01, (b) m ¼ 0.1, (c) m ¼ 1, and three values of b (uppermost curve within each figure: b ¼ 1, middle curve: b ¼ 2, lowest curve: b ¼ 5).
Incidence always increases with intraspecific competition (a), but in (c) where extrinsic mortality is high, the increase does not yield high cancer incidence
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DNA repair is a critical mechanism for cancer suppression
and somatic maintenance [54,55]. BRCA1 and BRCA2 (breast
cancer susceptibility genes 1 and 2) genes encode for tumour
suppressor proteins important in DNA repair pathways [56].
Mutations in these genes increase the risk for breast and ovar-
ian cancers [57]. Interestingly, one study demonstrated that
women with BRCA1 and BRCA2 mutations have greater sus-
ceptibility to breast cancer, but also higher fertility. Women
with BRCAmutations had significantly more children, shorter
birth intervals and end childbearing later than the controls [13].
However, the mechanism for increased fertility amongwomen
with BRCA mutations is unknown and murine models of
BRCA mutations do not support these findings [58].
Another potential example of an association between fertil-
ity and cancer risk involves the Kisspeptin (KISS1) gene in
humans. Kisspeptin is a G protein coupled receptor ligand
that is required for normal maturation and puberty. Defects
in KISS1 lead to the absence of sexual maturation, indicating
a critical role in the timing of puberty [59,60]. Kisspeptin also
induces production of luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) and is required for menstruation.
Interestingly, KISS1 was first discovered as a metastasis sup-
pressor gene and thought to play a role in suppression of
metastasis of breast cancers and melanomas [61]. Recently,
KISS1 has been also implicated in the inhibition of trophoblast
invasion and angiogenesis in the placenta [62,63]. Although
the exact mechanisms are yet to be determined, it may be
that the capacity to suppress trophoblast invasion might also
confer capacities to suppress cell invasion more generally and
thus reduce the risk of invasive/metastatic cancer.
Similarities in the underlying biological mechanisms of
cancer invasion and deep placentation, such as degradation
of the extracellular matrix and angiogenesis, suggest an evo-
lutionary link between these processes [64]. Effective
placental invasion may increase fertility at the cost of higher
cancer risk. Given that eutherian mammals vary in the
degree of placental invasiveness, cancer risk would be
expected to covary, and some evidence supports this predic-
tion. Equines and bovines have the least invasive placenta
type (epitheliochorial placentation) and were shown to have
lower rates of metastatic cancer than felines and canines, who
have characteristics of deeper placentation (endotheliochorial
placentation) [65]. Shallower placentation has evolved numer-
ous times across eutherian mammals [66], suggesting that
females of those species have also evolved mechanisms to
suppress trophoblast invasion, and these may be the same
underlying mechanisms that suppress metastatic disease.
Additional studies, linking metastatic cancer risk and placenta-
tion penetration using species with all placental types,
including thosewith themost invasive haemochorial placentas,
are needed to confirm this relationship.
(b) Environmental and ecological factors affect
the strength of trade-offs
The strength of a trade-off between cancer defence and
reproduction may be dramatically affected by ecological con-
ditions, especially available resources (when the trade-off is
due to energy allocation). Low resource levels have been
found to increase the intensity of trade-offs between reproduc-
tion and immune function in a number of species [6], including
the immunosuppressive effect of testosterone [67]. Differences
in the intensity of trade-offs between reproduction and survi-
val have been found in human populations with varying
levels of socio-economic status, with more intense trade-offs
between reproduction and longevity occurring in lower
socio-economic status groups [68–70]. This suggests that
environmental and ecological conditions are likely to play
important roles in modulating the intensity of trade-offs
between reproduction and cancer defence, especially when
this trade-off is mediated by energy allocations.
In our model, we explored the implications of varying the
intensity of the trade-off (b; figure 3). We found that in con-
ditions with higher trade-offs owing to decreased resource
availability (upper panels), elevated levels of cancer defence
result in very low fitness, especially when extrinsic mortality
is high. In contrast, in conditions with less intense trade-offs,
corresponding to more plentiful resources, high levels of
cancer defence result in extended lifespan and higher fitness.
The importance of both resource levels and extrinsic mor-
tality (which for non-humans may be caused by predation
or other ecological factors) in determining the fitness of vary-
ing levels of cancer defence suggests that future work should





Figure 5. Increased reproductive effort through mating effort or fertility may lower cancer defences. An illustration of our hypothesis– selection to enhance repro-
ductive competition decreases cancer defences. Traits selected to increase reproductive effort include body size, ornaments or weapons in males, or fertility frequency
and productivity in females. Hypothetical trade-offs are illustrated above depicting examples of reproductive competition. For example, the smaller antler on the deer
illustrates less reproductive competitiveness, but better protection against cancer. Similarly, increased reproductive output in domesticated chickens may trade off
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(c) Selection for rapid growth may mediate sexually
selected traits and cancer risk
Rapid growth may not only enhance within-species repro-
ductive competitiveness, but also lead to greater cancer
risk because of vulnerabilities associated with rapid cell pro-
liferation. The development and expression of many key
aspects of morphology and physiology influenced by sexual
selection and reproduction are mediated by growth factors,
including steroid hormones. Growth factors stimulate cell
proliferation and play a pivotal role in increasing growth
during development [71,72]. Growth factors are synthesized
in most tissues in the body and their action is modulated
by a network of molecules that promote cell cycle progres-
sion and inhibition of apoptosis [73]. Insulin signalling has
been proposed as the mechanism by which a variety of
organisms, from beetles to mammals, developmentally regu-
late expression of exaggerated structures, such as horns and
antlers [74]. IGF has also been implicated in numerous
cancer phenotypes [73,75,76]. Low levels of IGF-1 may
extend the time to malignant proliferation [77]. IGF-1
mutant mouse models live longer and are resistant to
cancer [78]. Increased levels of IGF may exacerbate cancer
phenotypes through a reduction in apoptosis, an increase in
cell turnover or an amplification of effects owing to DNA
damage. In humans, mutations in growth hormone receptor
genes have been found to be associated with lower cancer
risk [79]. Serum from these individuals was found to
reduce DNA breaks and increase apoptosis of human
epithelial mammary cells in culture [79].
Hormones control many of the physiological processes
involved in reproduction from development of sex organs
to the timing and frequency of reproduction. Growth factors,
and specifically steroid hormones, have been implicated
in the growth and progression of many cancers [80–84].
Steroid hormones bind to nuclear receptors within cells and
stimulate a complex signalling cascade involved in many cel-
lular actions, including proliferation. Larger body size and
larger ornaments or weapons can increase reproductive suc-
cess; however, this may lead to sexual antagonism and
favour reproductive competition over long-term survival
[85,86]. One important component of tumour suppression is
likely the suppression and slowing of somatic evolution.
However, organismal-level selection for growth may relax
constraints on somatic evolution within the body. Rapid pro-
liferation may be instantiated through a shorter generation
time, which could lead to a faster rate of somatic evolution.
A consequence of this may be greater susceptibility to
cancer in organisms selected for rapid growth.
(d) Does reproductive competition influence cancer risk
in humans?
Although cancer in the wild is poorly studied, predictions
from our model as well as a literature review find examples
where sexually selected traits—e.g. body size in fish and
antlers in deer—appear to influence cancer susceptibility in
these species. Do we see similar trends in humans, a much
better studied species with respect to cancer? Our model
suggests that differences in overall cancer risk between men
and women [87,88] might be partially explained by higher
reproductive competition in men than women. Within
sexes, reproductive competitiveness appears to be associated
with cancer risk for a number of traits. Taller men are repro-
ductively more successful than shorter men, indicating that
there is active selection for stature in some human popu-
lations [89–91]. In general, taller humans have an increased
risk for cancer susceptibility, including melanoma [92] and
testicular cancer [93]. Rapid growth prior to reproductive
maturity (i.e. becoming bigger faster) is also associated with
cancer in humans. Early growth in adolescents and the rate
of this growth can influence the risk of prostate cancer in
men [94] and breast cancer in women [95]. Outcome of
height in an individual depends on many growth factors,
including IGF [96]. As noted in §4c, low levels of IGF-1
have been associated with a decreased incidence to several
forms of cancer in animals and humans [76,97].
High testosterone levels are associated with increased
aggressiveness, high reproductive effort and mating success
[85,98–100]. Lifetime exposure to androgens, such as testos-
terone, appears to be associated with risk of prostate cancer
in human males [101]. However, this relationship has been
difficult to confirm, as prostate cancer typically has a late
age of onset, and testosterone diminishes with age [102].
Additionally, expression levels of androgen receptor, which
binds testosterone, may influence fertility in males [85,103]
and are associated with an increased risk of prostate cancer
[104]. There are open questions whether humans and other
species can facultatively trade off between cancer suppression
and reproductive competitiveness. Future work on adaptive
calibration of physiology based on physical and social
environmental inputs during development [105] could
provide insights into these open questions.
Within humans, energy budgets can affect the strength of
trade-offs between reproduction and somatic maintenance, as
seen in figure 3. Forager–horticulturalists, Tsimane, of the Bo-
livian Amazon live in a resource-limited environment
compared with those of industrialized societies. Tsimane
men are therefore likely to have stronger trade-offs between
reproduction (i.e. testosterone levels) and somatic maintenance
(i.e. immune function). Tsimane men, who live in caloric
restricted environments with high parasite load, have signifi-
cantly lower baseline levels of salivary testosterone when
comparedwithage-matchedUSmales [106]. Further, infections,
through exposures to pathogens and parasites dramatically
decrease testosterone levels [107]. Together, these results
suggest that with lower energy budgets there may be a stronger
trade-off between somatic maintenance (in the form of immune
function) and reproductive competitiveness (as measured by
circulating testosterone).
Reproductive competitiveness, including fertility timing,
frequency and attractiveness, may influence cancer suscepti-
bility in human females. High oestrogen levels are
associated with attractiveness in human females [108–110],
and oestrogen is an important component of follicle matur-
ation and oocyte quality [111]. However, the relationship
between reproduction and cancer risk in human females is
complex and differs for different types of cancer. Even
within breast cancer, a recent meta-analysis showed hormone
positive breast cancer has been associated with greater
exposure to cyclical hormones through earlier menarche,
later reproduction and lower parity, whereas hormone nega-
tive breast cancer is associated only with early menarche
[112]. These findings suggest that hormone positive breast
cancer risk may be explained by a mismatch between ances-





 on June 8, 2015http://rstb.royalsocietypublishing.org/Downloaded from 
that present-day women experience higher exposure to hor-
mones and suboptimally high rates of cell proliferation,
resulting in increased vulnerability to cancer. Hormone nega-
tive breast cancer risk, on the other hand, might be mediated
by other factors, including perhaps energetic trade-offs
favouring reproduction over somatic maintenance.
Other factors that may influence a women’s risk for cancer
include effects on fertility and pregnancy. As stated earlier,
women with BRCA1/2 mutations were shown to have
significantly different reproductive profiles than age-matched
controls. While BRCA1/2 mutations increase the risk for
breast cancer, these women had significantly more children
and shorter interbirth intervals [13], suggesting that there
may be a fertility advantage for BRCA mutations, possibly
accounting for the frequency of BRCA mutations in certain
human populations [113]. Additionally, physiological pro-
cesses involved in gestation, including placentation (as noted
in §4a) could influence disease risk. Humans have the most
invasive placental type, haemochorial. According to the posi-
tive pleiotropy hypothesis, which claims that placental
invasiveness should be correlated with susceptibility to meta-
static disease [65], a women’s cancer risk may be higher with
greater depth of placentation. Interestingly, a negative correl-
ation has been found between pre-eclampsia, characterized
by abnormally shallow placentation during pregnancy, and
breast cancer risk [114,115]. However, this does not hold true
for all populations studied [116], and there are likely additional
factors influencing cancer susceptibility.
5. Conclusion
The role of reproductive investment as a determinant of cancer
susceptibility is only beginning to be understood. Here, we
contribute to this emerging understanding by presenting a
model in which investment in reproductive competitiveness
occurs in the presence of a trade-off with investment in
cancer defence. We use this model to make predictions about
cancer incidence within and across species in various ecologi-
cal circumstances. Review of relevant literature reveals
several examples that are consistent with the model assump-
tions and predictions. Future comparative oncology and
genomic studies will be needed from species with diverse life
histories to tease apart the molecular underpinnings that may
influence both reproduction and cancer.
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